europeanpharmaceuticalreviewMarch 10, 2017
Tag: biosimilar , Biologics
The European Federation of Pharmaceutical Industries and Associations (EFPIA), European Biopharmaceutical Enterprises (EBE) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) have issued joint guidance for prescribers on switching between original reference biologics and biosimilars.
In their position paper, ‘Considerations for physicians on switching decisions regarding biosimilars’, the associations recommend that:
The position paper stresses that, due to the complex nature of biological molecules, any decision to switch should be made on a case-by-case basis and must be patient-, disease- and product-specific. It also urges physicians to balance the level of evidence against the level of risk or uncertainty in each case.
"A ‘one size fits all’ approach is not appropriate," it says.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: